Prokidney (PROK) EBITDA (2021 - 2026)

Prokidney (PROK) has 6 years of EBITDA data on file, last reported at -$44.9 million in Q1 2026.

• On a quarterly basis, EBITDA fell 8.57% year-over-year to -$44.9 million in Q1 2026; TTM through Mar 2026 was -$168.6 million, a 8.88% increase from a year earlier, with the FY2025 full-year figure at -$165.0 million, up 10.16% from the prior year.
• EBITDA for Q1 2026 stood at -$44.9 million, up from -$45.4 million in the prior quarter.
• Over the last five years, EBITDA for PROK reached as high as -$20.7 million in Q2 2022 and fell as low as -$66.5 million in Q1 2022.
• Historically, EBITDA has averaged -$41.1 million across 5 years, with a median of -$40.9 million in 2023.
• Across the five-year window, EBITDA tumbled 389346.01% in 2022 and surged 38.5% in 2023, its largest moves.
• Year by year, EBITDA stood at -$30.2 million in 2022, then increased by 19.93% to -$24.2 million in 2023, then slumped by 113.02% to -$51.6 million in 2024, then advanced by 12.02% to -$45.4 million in 2025, then gained by 0.97% to -$44.9 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$44.9 million in Q1 2026, -$45.4 million in Q4 2025, and -$38.5 million in Q3 2025.